Mallorie H. Fiero

Mallorie has been at the FDA since 2016 and is a statistical team leader supporting the Division of Oncology 1 (DO1) in the Office of Oncologic Diseases (OOD), which covers breast, gynecologic and genitourinary cancers. She received her BS in Statistics from UCLA and a PhD in Biostatistics from the University of Arizona where her research focused on missing data in cluster-randomized trials. Before her current role, she was a statistical reviewer in DO2 and DO3 covering gastrointestinal, thoracic head and neck, neuro-oncology, and other rare cancers. Mallorie has been heavily involved in patient-focused drug development (PFDD) in the Oncology Center of Excellence and CDER. Her research interests include estimands, missing data, and statistical analysis of patient-reported outcomes in cancer trials.